Novavax, Inc. (NVAX)
| Market Cap | 1.66B +22.2% |
| Revenue (ttm) | 413.80M -61.6% |
| Net Income | -247.73M |
| EPS | -1.52 |
| Shares Out | 164.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,061,663 |
| Open | 10.27 |
| Previous Close | 10.47 |
| Day's Range | 9.92 - 10.65 |
| 52-Week Range | 6.20 - 13.39 |
| Beta | 2.72 |
| Analysts | Buy |
| Price Target | 14.44 (+43.25%) |
| Earnings Date | Nov 5, 2026 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price target is $14.44, which is an increase of 43.25% from the latest price.
News
Novavax earns $125M milestone as Sanofi launches Phase 3 vaccine trial
Novavax (NVAX) has earned a $125M milestone payment with the initiation of Sanofi’s (SNY) Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax’s COVID-19 vaccine, Nuvaxovid. Sanofi’s...
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi'...
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. fin...
Novavax shareholder Shah Capital to step back from activist role
Shah Capital, one of Novavax's top shareholders, said on Friday it no longer seeks to influence control of the vaccine maker after restructuring into a family office.
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Novavax price target raised to $8 from $7 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps a Sell rating on the shares. The firm updated models in the…
Novavax price target raised to $8 from $7 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps an Underperform rating on the shares as part of a Q3 earnings…
Novavax Stock (NVAX) Plunges After WHO Calms Plague Fears
Shares of vaccine developer Novavax ($NVAX) plunged on Tuesday after the World Health Organization said that the risk of a wider plague outbreak remains low. The drop reversed part of…
Novavax Transcript: Citigroup’s Biopharma Back to School Summit 2026
The discussion highlighted a strategic shift to out-licensing and partnerships, with Sanofi and Pfizer driving near-term milestones and global expansion. Matrix-M's potential in oncology and infectious diseases is being explored, while NUVAXOVID's U.S. launch and combination vaccine prospects are set to drive growth.
Novavax Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A major strategic pivot has shifted focus to licensing and partnerships, with Matrix-M technology now central to both infectious disease and oncology pipelines. Key alliances with top pharma, strong financial milestones, and a leaner structure position the company for sustainable growth and global impact.
Novavax to Participate in September Investor Conferences
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Globa...
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Novavax’s (NVAX) partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European ...
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable toler...
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Novavax Earnings Call Transcript: Q2 2026
Q2 2026 saw strong progress in partnerships, notably with Sanofi and Pfizer, and a 76% year-over-year increase in product sales, despite lower total revenue due to prior year milestones. Operating expenses dropped 36%, and guidance was raised for 2026 revenue and profitability targets.
Novavax Quarterly report: Q2 2026
Novavax has published its Q2 2026 quarterly earnings report on August 6, 2026.
Novavax Earnings release: Q2 2026
Novavax released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Novavax Slides: Q2 2026
Novavax has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Novavax reports Q2 EPS (32c), consensus (38c)
Reports Q2 revenue $56.7M, consensus $53.3M. “We’re encouraged by the momentum we’re seeing across our business as we continue to advance our strategy,” said CEO John Jacobs. “As we enter…
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
Novavax raised its annual revenue forecast after beating quarterly expectations on Thursday, as the vaccine maker's licensing-driven milestone payments helped offset waning demand.
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanof...
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. fi...
Shah Capital Responds to Significant Shareholder Dissent at Novavax AGM
RALEIGH, N.C., June 24, 2026 (GLOBE NEWSWIRE) -- Shah Capital, the largest shareholder of Novavax, today commented on yesterday's announced voting results from Novavax's June 18th 2026 Annual Meeting ...